about
A neutralizing RNA aptamer against EGFR causes selective apoptotic cell deathDifferential SELEX in human glioma cell linesSelection of aptamers for mature white adipocytes by cell SELEX using flow cytometry.Aptamer-targeted cell-specific RNA interferenceFluorescence-activated cell sorting for aptamer SELEX with cell mixtures.GCPII imaging and cancer.New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization.Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic AgentsCell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cellsTargeting microRNAs in obesity.RNA Nanoparticles Derived from Three-Way Junction of Phi29 Motor pRNA Are Resistant to I-125 and Cs-131 Radiation.PTK7: a new biomarker for immunophenotypic characterization of maturing T cells and T cell acute lymphoblastic leukemiaAptamer-mediated delivery of chemotherapy to pancreatic cancer cellsSmooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells.Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery.Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.Multifunctional nanoscale platforms for targeting of the cancer cell immortality spectrum.Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.PET imaging in prostate cancer: focus on prostate-specific membrane antigenAptamers as targeted therapeutics: current potential and challenges.Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.Next-generation sequencing as input for chemometrics in differential sensing routines.Entropy-driven one-step formation of Phi29 pRNA 3WJ from three RNA fragments.Aptamer–biotin–streptavidin–C1q complexes can trigger the classical complement pathway to kill cancer cells.Mechanism of three-component collision to produce ultrastable pRNA three-way junction of Phi29 DNA-packaging motor by kinetic assessment.Nucleic acids in human glioma treatment: innovative approaches and recent resultsBeyond adhesion: emerging roles for integrins in control of the tumor microenvironment.Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics.Development of Phosphorothioate DNA and DNA Thioaptamers.Emerging Technologies of Polymeric Nanoparticles in Cancer Drug Delivery
P2860
Q28740749-4B6ECB4F-258E-43ED-A8AE-65D5515005E5Q28750173-57D60B54-60DB-4CA1-A858-990DFA6A1D23Q33638456-5F398ED1-590A-477E-A51C-6B4248F8A8C3Q33717239-E99619C8-FB05-4D27-A737-DEBED00AB401Q33762078-49C96142-8D86-44B8-9724-AFD66D825C54Q33827632-9B4CBF03-4E0A-4844-9657-D8D6AF54D742Q34459376-6B224557-DA81-4A2B-9951-1AED77215228Q35205365-4AF10F27-D715-4FF5-957E-95A14B38E86FQ35309726-3531B8B6-612F-42F3-AB6A-9D190E22CDFDQ35335653-98164B36-3081-473C-B506-326F445CE30FQ35400880-124DA03A-C25C-4142-B1A3-E8A990DCBD89Q35866025-E6B5075F-5702-42F4-8270-33880E47A13CQ36247609-58D455F5-2F10-4A7C-B01D-691A4190376CQ36298003-43150947-4C7A-41CB-9989-079D43F9066BQ36951272-9D5F098B-5EB1-4603-885D-542709463EBCQ37265632-4BCDEEAE-0D01-4E07-959B-819E6552718CQ37493869-286047F8-8058-49C6-93A8-89BD38F9E092Q37705970-A0EA1E5A-93B1-4B78-A8ED-DCA9747B9906Q37876825-B6B0E417-9BEE-41C3-A726-E7DFE99B55F9Q38093337-F54F643B-FB65-452D-98CF-B7D62B2A1227Q38099369-6F0A0E77-C514-4816-8631-805744723A9BQ38290290-F4768AB7-ADA5-4662-937A-F9075528CE91Q38774730-DA93778F-E497-4341-B571-A8961EE94920Q38892555-A5930910-45CC-4A38-9A68-EE5AE708F9C6Q39044626-1B0EEBAD-E32C-45F1-8B1F-FBB6CD9CD236Q39928986-6E1845A9-F6DD-4D0F-ACD5-A609487AEA2AQ40564594-86B1AE8E-BA73-462E-8A4E-A40CD65E1BBAQ42111511-E0FB993B-2E7B-4B48-A04C-361C43D9023DQ42353677-8C02C5A0-266F-47BA-A495-A5B1F00530E2Q48087924-6645AAD5-8CBD-4E6C-97CC-1DD35F24D4CBQ50893422-93965309-DFAE-487B-91A8-1FB0B7A3ACF8Q58690890-C4C95345-4DEE-439C-AA51-E2CFE9AA1B59
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cell-specific aptamers for targeted therapies.
@ast
Cell-specific aptamers for targeted therapies.
@en
type
label
Cell-specific aptamers for targeted therapies.
@ast
Cell-specific aptamers for targeted therapies.
@en
prefLabel
Cell-specific aptamers for targeted therapies.
@ast
Cell-specific aptamers for targeted therapies.
@en
P2860
P1476
Cell-specific aptamers for targeted therapies
@en
P2093
Paloma H Giangrande
Vittorio de Franciscis
P2860
P356
10.1007/978-1-59745-557-2_5
P407
P577
2009-01-01T00:00:00Z